导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 4.56% | 1304/4773 |
| 近一周 | 0.06% | 1159/5467 |
| 近一月 | -10.28% | 4730/5421 |
| 近一季 | 17.51% | 88/5238 |
| 近半年 | 4.01% | 975/4931 |
| 近一年 | -10.84% | 3384/4400 |
| 近两年 | 30.18% | 2247/2954 |
| 近三年 | -2.15% | 1960/2253 |
| 成立以来 | 24.37% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.43% 938/4961 |
-0.05% 3235/5312 |
- - |
- - |
| 2025 | 6.50% 2959/4813 |
3.88% 1025/3635 |
5.70% 553/4076 |
12.69% 3047/4524 |
-13.93% 4320/4813 |
| 2024 | -12.46% 2381/3463 |
-9.30% 2276/2808 |
-7.10% 2058/3014 |
10.82% 2588/3129 |
-6.26% 2639/3463 |
| 2023 | -11.75% 1422/2656 |
9.30% 414/2280 |
-8.77% 2013/2385 |
-9.97% 1920/2515 |
-1.71% 361/2655 |
| 2022 | -23.17% 1114/2207 |
-17.74% 1254/1919 |
7.11% 532/2016 |
-17.58% 1619/2113 |
5.82% 434/2208 |
| 2021 | 0.06% 731/1822 |
-8.72% 1092/1255 |
32.84% 32/1330 |
-13.37% 1340/1466 |
-4.75% 1493/1822 |
| 2020 | 44.11% 232/1250 |
9.37% 25/1028 |
36.91% 13/1067 |
-6.00% 1117/1164 |
2.39% 992/1184 |
| 2019 | 55.35% 73/1092 |
30.86% 227/739 |
-3.30% 379/788 |
9.23% 56/850 |
12.39% 36/918 |
| 2018 | -11.81% 78/834 |
- - |
5.25% 8/631 |
-8.81% 494/660 |
-18.29% 659/682 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 港股医疗ETF | 1.4546 | 31.90% |
| 华富中证港股通创新药指数型发起式A | 1.1637 | 30.96% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.3128 | 30.52% |
| 中欧中证港股通创新药指数发起A | 1.6103 | 30.52% |
| 嘉实中证港股通创新药指数发起式C | 0.8566 | 30.50% |
| 中欧中证港股通创新药指数发起C | 1.4583 | 30.44% |
| 永赢中证港股通医疗主题ETF发起联接A | 0.8927 | 30.26% |
| 景顺长城中证港股通创新药ETF联接C | 1.4696 | 29.97% |
| 华夏中证港股通医疗主题ETF发起式联接A | 0.8736 | 29.94% |
| 华夏中证港股通医疗主题ETF发起式联接C | 0.8719 | 29.88% |
| 银华中证全指医药卫生 VS. 长安沪深300非周期A(740101) |